Trinity Biotech plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Gillard
- Full Time Employees
- 287
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- IDA Business Park Bray WW Ireland A98 H5C8
- IPO Date
- Oct 21, 1992
- CIK
- 0000888721
- Website
- trinitybiotech.com
- Similar Companies
- Business
- Trinity Biotech plc (Nasdaq: TRIB) develops, manufactures, and markets diagnostic systems, including reagents and instrumentation, for point-of-care and clinical laboratory applications; its core products encompass rapid immunoassays such as TrinScreen and Uni-Gold for HIV-1/2 detection, tests for infectious diseases, sexually transmitted diseases, autoimmune disorders, haemoglobin variants including thalassemia screening via HPLC analyzers, diabetes monitoring through Hemoglobin A1c quantification, and raw materials supplied to the life sciences industry. The company, founded in 1992 and headquartered in Bray, Ireland, with facilities in Europe, the United States, and Canada, sells its offerings in over 110 countries to public health authorities, clinical laboratories, and reference labs via direct sales and a global distributor network. Recent developments include the December 2024 amendment to its credit agreement with Perceptive Advisors, securing approximately $5.5 million in additional liquidity through cash and payment-in-kind interest while extending a $5 million deferred payment for Waveform Technologies biosensor assets to November 2025 and issuing 1.5 million warrants; World Health Organization approvals in late 2024 and November 2025 for transferring late-stage manufacturing of TrinScreen and Uni-Gold HIV tests to lower-cost offshore partners as part of its Comprehensive Transformation Plan; a November 2025 collaboration with a bioinformatics partner to advance EpiCapture, a PCR-based epigenetic liquid biopsy for prostate cancer progression monitoring; and the acquisition of Waveform Technologies biosensor assets to enter the wearable continuous glucose monitoring market.
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
Trinity Biotech (TRIB) to Release Earnings on Wednesday
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
CompuMed (OTCMKTS:CMPD) & Trinity Biotech (NASDAQ:TRIB) Head-To-Head Review
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
Trinity Biotech Provides Business and Trading Update
Critical Review: Trinity Biotech (NASDAQ:TRIB) vs. Ayr Wellness (OTCMKTS:AYRWF)
Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement
Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation
Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026